Form 4 for RARE Ultragenyx Pharmaceutical Inc.
Accepted 2025-03-04 00:00:00 ET · period of report 2025-03-01 · accession 0000950170-25-032773 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-03-04 | 2025-03-01 | RARE | Harris Erik | EVP, Chief Commercial Off | A - Grant | $0.00 | +35.3K | 84.0K | +72% | $0 |
| D | 2025-03-04 | 2025-03-03 | RARE | Harris Erik | EVP, Chief Commercial Off | S - Sale | $42.10 | -15.1K | 87.9K | -15% | -$635.8K |
| D | 2025-03-04 | 2025-03-01 | RARE | Harris Erik | EVP, Chief Commercial Off | A - Grant | $0.00 | +30.2K | 30.2K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-01 | A | A | 18,443 | $0.00 | 102,419 | D | — | — | (F2) Represents shares of common stock which previously granted performance stock units were converted on March 1, 2025 upon certification of the performance metric. |
| 2 | Common | Common Stock | 2025-03-01 | A | A | 16,813 | $0.00 | 83,976 | D | — | — | (F1) Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date |
| 3 | Common | Common Stock | 2025-03-03 | S | D | 15,103 | $42.10 | 87,855 | D | — | — | (F3) Represents shares sold to pay required tax withholdings due to the vesting of RSUs. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.77 to $42.90 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. (F5) Includes 539 shares acquired under the Company's Amended & Restated Employee Stock Purchase Plan on April 30, 2024 and October 31, 2024 (F6) Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| 4 | Derivative | Stock Option (Right to Buy) | 2025-03-01 | A | A | 30,246 | $0.00 | 30,246 | D | $42.92 · — to 2035-03-01 | 30,246 Common Stock | (F7) On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |